Want to join the conversation?
$BIIB said that opicinumab also did not meet the secondary efficacy endpoint in Synergy study, which evaluated the slowing of disability progression, safety and pharmacokinetics. Synergy results will be presented at future medical meetings.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?
$YHOO is reporting today after market close. Nobody cares about this stock.